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Circulation: Cardiovascular Interventions
ORIGINAL ARTICLE

Excimer Laser Coronary Angioplasty in Coronary
Lesions
Use and Safety From the NCDR/CATH PCI Registry
Marc Sintek , MD; Edward Coverstone , MD; Richard Bach , MD; Alan Zajarias, MD; John Lasala, MD;
Howard Kurz , MD; Kevin Kennedy, MS; Jasvindar Singh , MD
BACKGROUND: Excimer laser coronary angioplasty (ELCA) uses an ultraviolet laser catheter for the treatment of coronary
artery disease. ELCA has been used for various coronary lesions, but current safety and frequency of use are unknown.
METHODS: We performed a retrospective, registry-based study of ELCA use during coronary interventions reported to the
National Cardiovascular Data Registry/CATH percutaneous coronary intervention registry from 2009 to 2018 (n=6 043 596
total interventions evaluated). The primary safety end point was the combination of any perforation, dissection, tamponade,
or death. ELCA use per 10 000 interventions was evaluated for the study duration. Subgroups of interest were identified
including in-stent restenosis lesions, saphenous vein graft lesions, chronic total occlusions, and thrombotic lesions.
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RESULTS: A total of 19 688 lesions were identified with ELCA use (0.3% of all lesions). The rate of ELCA use increased
across the study period from 14 ELCAs performed per 10 000 interventions in 2009 to 70 ELCAs performed per 10 000
interventions in 2018. The primary safety end point occurred in 4.2% of lesions and was higher than in cases where no ELCA
was used (3.0% P<0.001). After adjusting for baseline differences among the subgroups who received ELCA, the in-stent
restenosis group had the lowest rate of complications (odds ratio, 0.51 [95% CI, 0.42–0.63]), followed by the saphenous vein
graft group (odds ratio, 0.72 [95% CI, 0.5–1]). The chronic total occlusion group had a higher risk for complications (odds
ratio, 2.01 [95% CI, 1.61–2.40]).
CONCLUSIONS: The use of ELCA has remained low but has increased in recent years. Complications are significantly higher
when ELCA is used, but this effect is variable with respect to lesion subtype. ELCA is frequently used to treat in-stent
restenosis with a low risk of complication. ELCA use during chronic total occlusion interventions is associated with a
2-fold increased risk of complications. Together these findings provide guidance for lesion selection to optimize safety
with ELCA use.
GRAPHIC ABSTRACT: A graphic abstract is available for this article.
Key Words: coronary artery disease ◼ death ◼ dissection ◼ lasers ◼ percutaneous coronary intervention

I

nterventional cardiologists often face complex coronary lesions, including restenosis from prior stenting,
calcified lesions, bypass graft stenoses, chronic total
occlusions (CTO), and thrombotic lesions in the setting
of myocardial infarction. Excimer laser coronary angioplasty (ELCA) has been available for >25 years for the

percutaneous treatment of coronary artery stenoses, and
there has been renewed interest in its use for various
complex lesion subsets. ELCA uses a pulse waved, ultraviolet laser catheter that was first reported to vaporize
cadaveric atherosclerotic tissue with minimal thermal
damage in 1985.1 Thereafter, the first reports of clinical
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WHAT IS KNOWN
• Excimer laser coronary angioplasty (ELCA) is used
for treatment of complex lesions, including in-stent
restenosis, saphenous vein graft lesions, chronic
total occlusions, and thrombotic lesions, but has
been associated with coronary perforations and
dissections.

WHAT THE STUDY ADDS
• ELCA use has increased substantially over the
study time period and is associated with increased
complications.
• ELCA use for treatment of in-stent restenosis is
associated with less complications.
• ELCA use for the chronic total occlusion subset is associated with a 2-fold increased risk of
complications.
• This study helps to identify lesions where ELCA use
is safer.

Nonstandard Abbreviations and Acronyms
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CTO	chronic total occlusion
ELCA	excimer laser
coronary angioplasty
ISR	in-stent restenosis
NCDR/CATH PCI registry	National Cardiovascular Data Registry/
CATH Percutaneous
Coronary Intervention
registry
SVG
saphenous vein graft

use in coronary stenoses showed significant luminal gain
with low complication rates.2,3 ELCA was shown to be
effective in coronary lesions found to be poorly treated
with balloon angioplasty alone, including aorto-ostial
lesions, long calcified lesions, and saphenous vein graft
(SVG) lesions.4,5 Enthusiasm for ELCA was tempered
by elevated complication rates compared with percutaneous transluminal coronary angioplasty alone,6 further
reports suggesting a marginal benefit of luminal gain
with ELCA pretreatment7 and the refinement of coronary
stents and other atherectomy devices, such as rotational
atherectomy.8 More recently, ELCA has seen a resurgence for use in complex coronary disease in some centers9 and has shown effectiveness in the treatment of
in-stent restenosis (ISR),10 debulking of SVG lesions,11
facilitating CTO interventions,12 and treatment of thrombotic lesions.13 A recent large registry study from the UK
confirmed an increased use of ELCA with an additional
increased risk of dissection, perforation, and slow flow
compared with non-ELCA interventions.14

Although evidence suggests an increase in the use
of ELCA, the magnitude of this increase is unknown in
current US practice. In addition, current safety and complications related to ELCA use and ELCA use in complex
lesion subsets is unknown. The National Cardiovascular
Data Registry/CATH percutaneous coronary intervention
(NCDR/CATH PCI) registry provides a robust registry
with over 2400 participating hospitals and over 6 million
interventions performed since 2009.15 This study sought
to investigate overall ELCA use and rates of complications in the NCDR/CATH PCI registry, and the safety
of ELCA use in lesion subsets of interest, including ISR
lesions, SVG lesions, CTO, and thrombotic lesions.

METHODS
Because of the nature of the data collected for this study,
requests to access the data set from qualified researchers
trained in human subject confidentiality protocols may be sent
to NCDR/CATH PCI registry. We performed a retrospective,
registry-based study of ELCA use during coronary interventions
using version 4.4 of the NCDR/CATH PCI registry. Approval for
the project was obtained through the NCDR/CATH PCI registry Research and Projects committee and review committee,
including research oversight on human subjects with deidentified data. Approximately 6 million coronary interventions from
2009 until 2018 were queried for use of ELCA during the intervention using prespecified data fields for ELCA use (field 7225
with the following: Device 275 ELCA Coronary Laser Catheter
Rx or Device 276 ELCA Coronary Laser Catheter over the
wire). A priori cohorts were then identified for complex lesion
subsets as follows: thrombotic lesions (field 7195=yes and
field 7175=not in graft and field in-stent thrombosis 7165=no),
CTOs (field 7120=yes), ISR (field 7160=yes), and SVG lesions
(field 7175=vein). The registry was also queried and the primary end point analyzed for any PCI, any CTO PCI, and any ISR
PCI for comparison with ELCA use in these groups.

Study End Points
The primary end point for the study was the combined complication end point of any perforation, dissection, tamponade, or
death before discharge from the index procedure. A secondary
combined end point of any perforation, dissection, or tamponade was also evaluated. Absolute ELCA use per 10 000 interventions was evaluated for each quarter available in the registry.

Statistical Analysis
Data are shown as mean±SD for continuous and n (%) for
categorical variables, and compared using the Student t test
or χ2 testing where appropriate. A multivariable regression
model was created using significant and clinically important
covariates using a hierarchical logistic regression model with
a random intercept for site. The primary exposure variable for
this model was specific lesion characteristics (thrombotic, SVG,
ISR, CTO, multiple, and none), and we adjusted for the following variables: presentation (ST-segment–elevation myocardial
infarction, non–ST-segment–elevation myocardial infarction,
and nonmyocardial infarction), age, diabetes, prior shock, prior
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arrest, prior pad, and dialysis. The complication rate over time
was compared using the Cochran-Armitage test.

RESULTS
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Using the most current NCDR/CATH PCI registry,
19 688 lesions were identified where ECLA was performed (0.3% of total lesions available). The overall rate
of ELCA use during the study was 33 lasers performed
per 10 000 interventions, with a significant increase in
ELCA use observed starting around 2014 (Figure 1).
ELCA was used in 14 cases per 10 000 interventions in
2009 and increased 5-fold to 70 cases per 10 000 interventions in 2018. The overall complication rate for the
combination of death, cardiac tamponade, any dissection, or any perforation was 4.2% and was higher than
in cases where no ELCA was used (3.0% P<0.001). The
overall complication rate for the combination of cardiac
tamponade, any dissection, or any perforation was 2.7%
and was also higher than in cases where no ELCA was
used (1.4% P≤0.001). There was no increased risk of inhospital death in cases where ELCA was used compared
with cases where no ELCA was used (1.7% versus 1.7%;
P=0.53). Compared with interventions where no ELCA
was used, the interventions where ELCA was used were
more likely to be in patients with prior coronary artery
bypass grafting (33.9% versus 17.6%, P<0.001), diabetes(49.8% versus 38.3%, P<0.001), peripheral vascular
disease (21% versus 12.3%, P<0.001), end-stage renal

ELCA Use and Safety in NCDR/CATH PCI Registry

disease (4.8% versus 2.7%, P<0.001), and left ventricular systolic dysfunction (16.6% versus 11.8%, P<0.001),
and they required significantly longer fluoroscopy time to
complete the procedure (26.6±20 versus 15.2±12 minutes, P<0.001; Table I in the Data Supplement). Radial
access was higher in the group with ELCA use (25%
versus 23%; P<0.001). ELCA use significantly increased
over the study period but the complication rate remained
similar (P=0.169 for primary combined end point and
P=0.385 for combined secondary end point; Figure 1).
There was high variability in rates of complications per
quarter, likely influenced by small sample sizes in which
ELCA was used, until ELCA use increased significantly
towards the end of 2015. There were significant differences in complications among the various lesions subsets treated (Table 1). There were 7469 lesions that did
not meet a lesion subset definition. There were 6249
ISR only lesions, 1196 SVG only lesions, 1685 CTO
only lesions, and 936 thrombus only lesions (Figure 2A).
There were 2153 lesions that met multiple lesion definitions (Figure 2A). The use of ELCA in all lesion subsets
increased over the study but use in the ISR group was the
most pronounced (Figure 2B). The rate of the combination of death, cardiac tamponade, any dissection, or any
perforation associated with ELCA use was highest in the
group of patients with thrombotic lesions (8.0% versus
all other ELCA lesions 3.9%, P<0.001). This was driven
by a higher incidence of death (5.1% versus all other
lesions 1.5%, P<0.001) that may have been related to a

Figure 1. Excimer laser coronary angioplasty (ELCA) use and complication rate in the National Cardiovascular Data Registry/
CATH percutaneous coronary intervention (NCDR/CATH PCI) registry version 4.4.
ELCA use is reported per 10 000 interventions for each year_quarter available. The rate of the combined primary end point of any perforation, dissection,
tamponade, or death before discharge from the index procedure is plotted for each quarter and is not significantly different over time (P=0.169).
Circ Cardiovasc Interv. 2021;14:e010061. DOI: 10.1161/CIRCINTERVENTIONS.120.010061
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Table 1. Baseline Characteristics and Complication Frequency in All Patients Treated With Laser Atherectomy and in Patients
Treated With Laser Atherectomy in Prespecified Subgroups
Variable

Overall, N=19 688

ISR, N=8128

SVG, N=2130

Thrombotic, N=1298

CTO, N=2849

Age, y

68±11

66.5±10.9

70.8±10.0

64.3±12.8

65.5±11

Male

13 956 (70.9%)

5672 (69.8%)

1638 (76.9%)

934 (72%)

2145 (75.3%)

Hypertension

17 913 (91%)

7650 (94.1%)

2003 (94.1%)

1022 (78.7%)

2589 (90.9%)

Hyperlipidemia

17 585 (89%)

7674 (94.5%)

2006 (94.2%)

974 (75.1%)

2630 (92.3%)

Diabetes

9806 (49.8%)

4390 (54%)

1136 (53.4%)

498 (38.4%)

1423 (50%)

Prior MI

9366 (47.6%)

4757 (58.5%)

1229 (57.7%)

434 (33.4%)

1489 (52.3%)

Peripheral arterial disease

4135 (21%)

1926 (23.7%)

653 (30.7%)

182 (14%)

599 (21%)

Any LV dysfunction

3269 (16.6%)

1394 (17.2%)

436 (20.5%)

170 (13.1%)

591 (20.7%)

STEMI/NSTEMI at presentation

4110 (20.9%)

1448 (17.8%)

597 (28%)

756 (58.2%)

303 (10.6%)

Cardiogenic shock

300 (1.5%)

80 (1.0%)

31 (1.5%)

81 (6.2%)

31 (1.1%)

Any tamponade

75 (0.4%)

17 (0.2%)

5 (0.2%)

8 (0.6%)

18 (0.6%)

Significant dissection

271 (1.4%)

65 (0.8%)

14 (0.7%)

26 (2.0%)

71 (2.5%)

Any perforation

275 (1.4%)

68 (0.8%)

19 (0.9%)

19 (1.5%)

101 (3.5%)

Acute kidney injury

1645 (10.2%)

618 (9.5%)

215 (11.7%)

140 (12.3%)

188 (8.3%)

Emergency CABG

157 (0.8%)

40 (0.5%)

7 (0.3%)

14 (1.1%)

15 (0.5%)

Death before discharge

344 (1.7%)

90 (1.1%)

43 (2.0%)

66 (5.1%)

43 (1.5%)

Baseline characteristics

Complications

A total of 7469 lesions were not associated with any lesion subset, 1196 were SVG only, 6249 were ISR only, 1685 were CTO only, and 936 were thrombus only.
A total of 2153 lesions contained multiple subsets, the most common being 850 CTO+ISR lesions. CABG indicates coronary artery bypass grafting; CTO, chronic total
occlusion; ISR, in-stent restenosis; LV, left ventricle; MI, myocardial infarction; PCI, percutaneous coronary intervention; STEMI/NSTEMI, ST-segment–elevation/non–STsegment–elevation myocardial infarction; and SVG, saphenous vein graft.
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higher incidence of cardiogenic shock (4.4% versus all
other lesions 1.1%; P<0.001), and ST-segment–elevation myocardial infarction (30.5% versus all other lesions
2.6%, P<0.001). The rate of the combination of death,
cardiac tamponade, any dissection, or any perforation
associated with ELCA use was also higher in patients
with CTO lesions (6.7% versus all other ELCA lesions
3.7%, P<0.001) and was lowest in the patients with ISR
(2.5% versus all other ELCA lesions 5.3%, P<0.001) and
patients with SVG lesion (3.3% versus all other ELCA
lesions 4.3%; P=0.04). Excluding death, the rate of the
combination of cardiac tamponade, any dissection, or
any perforation was highest in the CTO group (5.8%
versus all other ELCA lesions 2.2%, P<0.001), followed
by the thrombotic lesion group (3.7% versus all other
ELCA lesions 2.6%, P=0.02), and was lowest in the ISR
lesion group (1.6% versus all other ELCA lesions 3.5%,
P<0.001) and SVG lesion group (1.4% versus all other
ELCA lesions 2.8%, P<0.001). After adjusting for baseline differences between lesion subsets, there remained
a significant association between CTO interventions and
complications with ELCA use, whereas the ISR and SVG
had the lowest complication rates (Table 2). After adjusting for baseline differences between lesion subsets, use
of ELCA in the thrombotic lesion group was not associated with increased complications (Table 2). Applying
this same model to ELCA versus non-ELCA lesions in
these subgroups; ELCA was significantly associated with

an increased rate of complications (Table II in the Data
Supplement). Other significant predictors of the rate
of complication were increasing age, acute myocardial
infarction, and cardiogenic shock (Table 2). There were a
significant number of lesions that were not included in a
prespecified subgroup. These lesions had similar complication rates as those lesions placed into a subgroup of
interest (Table III in the Data Supplement).
In 16 812 CTO procedures in the NCDR/CATH PCI
registry where ELCA was not used, the combined end
point of death, cardiac tamponade, any dissection, or any
perforation was 3.7% compared with 6.7% in patients
where ELCA was used (P<0.001). For the secondary
end point of cardiac tamponade, any dissection, or any
perforation, the rate was still significantly higher among
CTO procedures when ELCA was used than CTO procedures where ELCA was not used (5.8% versus 2.2%,
P<0.001). Dissection (2.5% versus 1.2%, P<0.001),
perforation (3.5% versus 1.0%, P<0.001), and tamponade (0.6% versus 0.3%, P=0.02) were all significantly
higher in the CTO group where ELCA was used compared with the CTO group where ELCA was not used.
In contrast, among 622 658 procedures performed for
ISR without ELCA use in the NCDR/CATH PCI registry, the combined end point of death, cardiac tamponade,
any dissection, or any perforation was 2.2% compared
with 2.5% in patients where ELCA was used (P<0.021).
For the combined end point of cardiac tamponade, any
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Figure 2. Excimer laser coronary angioplasty (ELCA) lesion subset analysis.
A, Total number of ELCA cases analyzed and frequency of subgroups treatments over the study duration. B, Quarterly trend in absolute number of
lesion subsets treated with ELCA over the study period. CTO indicates chronic total occlusion; ISR, in-stent restenosis; and SVG, saphenous vein graft.

dissection, or any perforation, ELCA use during ISR procedures resulted in complications in 1.6% versus 1.1%
(P<0.001) in procedures where ELCA was not used. The
rate of perforation was less in the group where ELCA
was used (0.8% versus 1.8%, P<0.001).

DISCUSSION
ELCA has long been available for use in the percutaneous treatment of coronary artery disease, and herein, we
report the largest study to date examining safety and

Circ Cardiovasc Interv. 2021;14:e010061. DOI: 10.1161/CIRCINTERVENTIONS.120.010061

July 2021

705

Sintek et al

ELCA Use and Safety in NCDR/CATH PCI Registry

Table 2. Multivariable Model Comparing the Combined End Point of Death, Perforation, Dissection, or Cardiac Tamponade (End Point 1) or the Combined End Point of Perforation, Dissection, or Cardiac Tamponade (End Point 2) in Important Subgroups Where ELCA Was Used
Combined end point 1

Combined end point 2

Variable

Odds ratio (95% CI)

P value

Odds ratio (95% CI)

P value

Thrombus only

1.18 (0.87–1.61)

0.29

1.15 (0.75–1.78)

0.51

SVG only

0.72 (0.52–1)

0.05

0.49 (0.31–0.79)

0.004

ISR only

0.51 (0.42–0.63)

<0.0001

0.45 (0.35–0.58)

<0.0001

CTO only

2.01 (1.61–2.49)

<0.0001

2.31 (1.82–2.92)

<0.0001

Multiple subsets

0.93 (0.72–1.18)

0.53

0.95 (0.71–1.27)

0.75

STEMI

1.76 (1.3–2.39)

0.0003

0.55 (0.31–0.98)

0.04

NSTEMI

1.36 (1.15–1.32)

0.001

1.07 (0.84–1.36)

0.60

Age (+10 y)

1.23 (1.15–1.32)

<0.0001

1.1 (1.01–1.19)

0.02

Diabetes

1.1 (0.95–1.27)

0.22

0.9 (0.75–1.07)

0.22

PAD

1.33 (1.12–1.57)

0.001

1.24 (1–1.52)

0.045

Current dialysis

1.43 (1.07–1.91)

0.015

0.7 (0.43–1.15)

0.16

Cardiogenic shock

9.74 (7.29–13.02)

<0.0001

0.89 (0.4–2)

0.78

Cardiac arrest

1.72 (1.07–2.77)

0.025

1.28 (0.44–3.72)

0.65

A total of 7469 lesions were not associated with any lesion subset, 1196 were SVG only, 6249 were ISR only, 1685 were
CTO only, and 936 were thrombus only. A total of 2153 lesions contained multiple subsets. CTO indicates chronic total occlusion; ELCA, excimer laser coronary angioplasty; ISR, in-stent restenosis; PAD, peripheral arterial disease; STEMI/NSTEMI,
ST-segment–elevation/non–ST-segment–elevation myocardial infarction; and SVG, saphenous vein graft.
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complication rates associated with its use. Despite a significant increase in use of ELCA over the past 4 to 5 years,
the overall use of ELCA still remains low. Complications
with ECLA use are significantly greater than interventions
without ELCA use, but this effect varies among types of
lesions treated. Our data suggest that ELCA use during
CTO procedures is associated with a 2-fold increased risk
of complications, while ELCA use during treatment of ISR
and SVG lesions is associated with a lower risk of complications. Together these findings provide guidance for
lesion selection to optimize safety with ECLA use.
Litvack et al16 published the largest ELCA experience
to date analyzing complications and effectiveness in nearly
3000 patients treated with ELCA.16 ELCA success was
high and improved with operator experience. In-hospital
death occurred in 0.5% of patients, perforation occurred in
1% of patients, and coronary dissection occurred in 13%.
Perforation occurred in upwards of 2% of ELCA cases in
a large case series reported by Ellis et al.6 Thereafter, complications related to ELCA were shown to be mitigated by
continuous saline administration.17 In addition, the current
laser catheter has also undergone modifications, making it
smaller and potentially providing a safer device. The most
recent data from 119 patients treated with current ELCA
catheters and techniques showed a dissection rate of
3%, a perforation rate of 1.7% and no procedure-related
deaths. Complications were more common among lesions
classified as CTOs.18 Protty et al14 published a large, retrospective evaluation of ELCA use in the United Kingdom. In
1471 ELCA cases, there was an increased risk of perforation (1.7% versus 0.3%; P<0.01), dissection (4.1% versus
1.7%, P<0.01), and in-hospital unadjusted death (2.2%

versus 1.4%; P=0.01). Our current study draws upon a
much larger, real-world evaluation of ELCA use and safety
but has very similar findings as the recently published UK
ELCA experience. Among nearly 20 000 procedures with
documented ELCA usage, the complication rate for the
combination of death, cardiac tamponade, any dissection,
or any perforation was low at 4.2%. The rate of dissection and perforation was 1.4% and 1.4%, respectively, in
procedures where ELCA was used. These complications
are higher than in lesions where no ELCA was used; for
example, perforation was nearly 3-fold higher in the ELCA
group (1.4% versus 0.4%, P<0.001). However, ECLA
was used in patients with greater comorbid illnesses and
longer procedure times, suggesting higher baseline risk
for adverse outcomes. We speculate that operators are
choosing ELCA for lesion and patient characteristics that
are associated with a greater risk of complications compared with routine PCI, and this will bias observed complication rates. ELCA complication rates reported herein
also compare favorably with other atherectomy devices,
such as rotational atherectomy.19 Importantly, the observed
complication rate has not significantly changed despite a
nearly 5-fold increase in the use of ELCA. We also identified characteristics, such as acute myocardial infarction
and cardiogenic shock, where complications may be high.
Avoidance of ELCA use in these scenarios could lower the
rate of complications further.
This study further supports the ideal of careful case
selection in choosing an atherectomy device. There were
important differences in complications with respect to
the types of lesions being treated with ELCA. ELCA has
shown effectiveness in the treatment of restenosis within
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both bare metal and drug-eluting stents especially with
stent underexpansion.10,20–23 ELCA treatment of restenotic lesions compared with cutting balloon angioplasty
showed less vessel damage by optical coherence tomography, improved 6-month lumen late loss, and a strong
trend towards lower target lesion revascularization.24 ISR
was the most frequently represented lesion subset in our
study with nearly 40% of lesions treated with ELCA in
this registry involving restenosis. Importantly, this subset
also had a low rate of complications and was comparable
to PCI in lesions where laser was not used; the complication rate for the combination of cardiac tamponade,
any dissection, or any perforation was 1.6% with ELCA
compared with 1.1% without ELCA (P≤0.001), with a
notable lower incidence of perforation. Possible mechanistic explanations of this include a reduction in need for
aggressive predilatation and possible coronary trauma
from balloon rupture or over distension. ISR appeared
to be protective against complications from ELCA compared with other ELCA lesion subgroups with an adjusted
HR of 0.51 (95% CI, 0.42–0.63) for the combination of
cardiac tamponade, any dissection, any perforation, or
death. Although there is limited, large-scale efficacy data
for ELCA use in ISR treatment, this safety data suggests
the risk associated with ELCA is lower when treating ISR.
The same cannot be said for ELCA use in lesions
identified as a CTO. ELCA has found important roles for
the treatment of CTO including modification of the proximal lesion cap to facilitate wire entry.12 Clearly, CTO interventions are more complex and as such associated with
higher risks of perforation and dissection. In most cases,
dissection and luminal reentry has been adopted as the
route for successful CTO intervention. However, the
complication rate for the combination of cardiac tamponade, any dissection, or any perforation was significantly
elevated in the CTO procedures where ELCA was used
compared with CTO procedures where ELCA was not
used in the NCDR registry (5.8% versus 3.2%, P<0.001).
Even after adjusting for confounders between ELCA
lesion subgroups, there was a nearly 2-fold increased
rate of serious complications related to ELCA use during
CTO interventions. This study is unable to suggest a
mechanism for this increased risk. Although we might
speculate that the increased risk may be related to use
of larger laser catheters, high energy levels, or differing amounts of flush, it may ultimately be related to
a confounder such as the difficulty of the CTO intervention that cannot be measured. Importantly, off-label
techniques such as proximal cap modification without
a guidewire could not identified in this registry. This
study does highlight the need for caution with ELCA
use in CTO interventions, with 23% (n=192 out of a
total of 810 total complications) of the entire cohort
complications arising from the CTO group, highlighting
a need to understand how to make ELCA use safer in
this lesion subset.

ELCA Use and Safety in NCDR/CATH PCI Registry

Limitations
This study is subject to the quality and accuracy of a
large, national, self-reported registry. Although generally regarded as accurate, ELCA use, lesion characteristics, outcomes, and complications were self-reported. In
addition, associations observed between ELCA use and
end points cannot determine causality. Additionally, the
technique used, including saline contrast flush or use of
contrast, cannot be accounted for nor can the complexity
of cases in which ELCA was used. There is clear selection bias for ELCA use which cannot be accounted for.
Finally and most importantly, there is no longitudinal data
regarding efficacy of ELCA.

Conclusions
The use of ELCA in PCIs has seen an increase, although
overall use remains low. ELCA is associated with a
higher risk of complications compared with non-ELCA
PCI, but there is important differences in complications
with respect to various lesion types. In the NCDR registry,
ELCA is frequently used to treat ISR and has a lower
risk of serious complication in this lesion type. ELCA
use during CTO interventions is associated with a 2-fold
increased risk of complications. Further research is
needed with regards to efficacy of ELCA in these lesions
subtypes, but this study highlights lesion selection for
ELCA use where there is a strong safety profile.
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